The role of intravitreal trimethoprim/sulfamethoxazole in the treatment of toxoplasma retinochoroiditis

Himadri Choudhury; Animesh Jindal; Avinash Pathengay; Abhishek Bawdekar; Thomas Albini; Harry W. Flynn

doi:10.3928/23258160-20150101-27

The role of intravitreal trimethoprim/sulfamethoxazole in the treatment of toxoplasma retinochoroiditis

Himadri Choudhury, Animesh Jindal, Avinash Pathengay, Abhishek Bawdekar, Thomas Albini, Harry W. Flynn

Ophthalmology

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

The authors evaluate the role of intravitreal trimethoprim/sulfamethoxazole in the treatment of toxoplasma retinochoroiditis (TRC) in four patients. Intravitreal injection of trimethoprim/sulfamethoxazole 1.28 mg/0.08 mL with dexamethasone 400 ?g/0.1 mL was injected weekly or biweekly. After the initiation of treatment, a reduction in intraocular inflammation was observed clinically and on optical coherence tomography within 1 week. Three patients regained visual acuity of 20/20, and one patient improved to 20/40 with residual macular scarring. No evidence of retinal toxicity was noted on full-field electroretinogram. Intravitreal trimethoprim/sulfamethoxazole and dexamethasone combination may be an alternative treatment strategy in patients with TRC.

Original language	English (US)
Pages (from-to)	137-140
Number of pages	4
Journal	Ophthalmic Surgery Lasers and Imaging Retina
Volume	46
Issue number	1
DOIs	https://doi.org/10.3928/23258160-20150101-27
State	Published - Jan 1 2015

ASJC Scopus subject areas

Surgery
Ophthalmology

Access to Document

10.3928/23258160-20150101-27

Fingerprint Dive into the research topics of 'The role of intravitreal trimethoprim/sulfamethoxazole in the treatment of toxoplasma retinochoroiditis'. Together they form a unique fingerprint.

Cite this

The role of intravitreal trimethoprim/sulfamethoxazole in the treatment of toxoplasma retinochoroiditis. / Choudhury, Himadri; Jindal, Animesh; Pathengay, Avinash; Bawdekar, Abhishek; Albini, Thomas ; Flynn, Harry W.

In: Ophthalmic Surgery Lasers and Imaging Retina, Vol. 46, No. 1, 01.01.2015, p. 137-140.

Research output: Contribution to journal › Review article › peer-review

@article{b161b2a64a804a3b85c0e351e11d7e3b,

title = "The role of intravitreal trimethoprim/sulfamethoxazole in the treatment of toxoplasma retinochoroiditis",

abstract = "The authors evaluate the role of intravitreal trimethoprim/sulfamethoxazole in the treatment of toxoplasma retinochoroiditis (TRC) in four patients. Intravitreal injection of trimethoprim/sulfamethoxazole 1.28 mg/0.08 mL with dexamethasone 400 ?g/0.1 mL was injected weekly or biweekly. After the initiation of treatment, a reduction in intraocular inflammation was observed clinically and on optical coherence tomography within 1 week. Three patients regained visual acuity of 20/20, and one patient improved to 20/40 with residual macular scarring. No evidence of retinal toxicity was noted on full-field electroretinogram. Intravitreal trimethoprim/sulfamethoxazole and dexamethasone combination may be an alternative treatment strategy in patients with TRC.",

author = "Himadri Choudhury and Animesh Jindal and Avinash Pathengay and Abhishek Bawdekar and Thomas Albini and Flynn, {Harry W.}",

year = "2015",

month = jan,

day = "1",

doi = "10.3928/23258160-20150101-27",

language = "English (US)",

volume = "46",

pages = "137--140",

journal = "Ophthalmic Surgery Lasers and Imaging Retina",

issn = "2325-8160",

publisher = "Slack Incorporated",

number = "1",

}

TY - JOUR

T1 - The role of intravitreal trimethoprim/sulfamethoxazole in the treatment of toxoplasma retinochoroiditis

AU - Choudhury, Himadri

AU - Jindal, Animesh

AU - Pathengay, Avinash

AU - Bawdekar, Abhishek

AU - Albini, Thomas

AU - Flynn, Harry W.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The authors evaluate the role of intravitreal trimethoprim/sulfamethoxazole in the treatment of toxoplasma retinochoroiditis (TRC) in four patients. Intravitreal injection of trimethoprim/sulfamethoxazole 1.28 mg/0.08 mL with dexamethasone 400 ?g/0.1 mL was injected weekly or biweekly. After the initiation of treatment, a reduction in intraocular inflammation was observed clinically and on optical coherence tomography within 1 week. Three patients regained visual acuity of 20/20, and one patient improved to 20/40 with residual macular scarring. No evidence of retinal toxicity was noted on full-field electroretinogram. Intravitreal trimethoprim/sulfamethoxazole and dexamethasone combination may be an alternative treatment strategy in patients with TRC.

AB - The authors evaluate the role of intravitreal trimethoprim/sulfamethoxazole in the treatment of toxoplasma retinochoroiditis (TRC) in four patients. Intravitreal injection of trimethoprim/sulfamethoxazole 1.28 mg/0.08 mL with dexamethasone 400 ?g/0.1 mL was injected weekly or biweekly. After the initiation of treatment, a reduction in intraocular inflammation was observed clinically and on optical coherence tomography within 1 week. Three patients regained visual acuity of 20/20, and one patient improved to 20/40 with residual macular scarring. No evidence of retinal toxicity was noted on full-field electroretinogram. Intravitreal trimethoprim/sulfamethoxazole and dexamethasone combination may be an alternative treatment strategy in patients with TRC.

UR - http://www.scopus.com/inward/record.url?scp=84920728617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920728617&partnerID=8YFLogxK

U2 - 10.3928/23258160-20150101-27

DO - 10.3928/23258160-20150101-27

M3 - Review article

C2 - 25559528

AN - SCOPUS:84920728617

VL - 46

SP - 137

EP - 140

JO - Ophthalmic Surgery Lasers and Imaging Retina

JF - Ophthalmic Surgery Lasers and Imaging Retina

SN - 2325-8160

IS - 1

ER -